AI's New Gatekeepers: How Two Pharma Giants Control the Beauty Economy

BOCA RATON, FL – June 23, 2026 – The invisible hand of the market is increasingly becoming an algorithmic one. In the booming $25 billion U.S. aesthetic medicine industry, the patient journey no longer begins with a web search or a social media scroll, but with a question posed to an AI. A groundbreaking new report reveals who is providing the answers—and the results paint a stark picture of concentrated power.

The Med Spa & Aesthetic Medicine AI Visibility Index 2026, released today by 5W AI Communications, is the first study to defensibly measure how platforms like ChatGPT, Gemini, and Google’s AI Overviews are funneling prospective patients. Its central finding is a tectonic shift in market dynamics: just two pharmaceutical companies, AbbVie (via its Allergan Aesthetics unit) and Galderma, now control a staggering 80% of all drug and device citations within these AI-powered answers. AbbVie, owner of iconic brands like Botox and Juvederm, commands 47% of this new digital real estate, while Galderma, with its Dysport and Restylane lines, holds 33%.

This concentration of visibility is not merely a curiosity of the new AI-driven landscape; it is the new architecture of the patient pipeline. "Citation share is the new market share," stated Ronn Torossian, founder and chairman of 5W AI Communications. "The brands that don't appear in AI answers are excluded from consideration before the patient ever calls a clinic."

The New Digital Landlords

The dominance of AbbVie and Galderma was not built by accident. It is the result of years of cultivating the very signals that AI models are trained to value: authority, clinical validation, and widespread recognition. The report's methodology, which analyzed 65 distinct patient-intent queries across five major AI engines, shows that brands with deep, peer-reviewed clinical data and clear FDA documentation are disproportionately cited. These pharmaceutical giants have invested heavily in manufacturer-owned educational hubs and sustained editorial placements, creating a vast repository of authoritative content that AI systems naturally harvest and present as fact.

Botox, for example, achieved a near-perfect score of 95 out of 100, becoming functionally synonymous with wrinkle treatments in the AI's vocabulary. This reflects a long-term strategy where the brand, the drug, and the entire treatment category have merged in the public—and now algorithmic—consciousness.

This strategic content moat is a core component of what is now being called Generative Engine Optimization (GEO), a new discipline focused on making content discoverable, extractable, and citable for AI. Unlike traditional SEO, which prioritizes ranking on a results page, GEO is about becoming part of the answer itself. The success of AbbVie and Galderma demonstrates a mastery of this new domain, effectively making them the digital landlords of aesthetic medicine, with nearly every other market participant now a tenant.

A Widening 'Visibility Gap'

While the pharma titans consolidate their hold, the report exposes a troubling chasm it calls the "Visibility Gap." The top 25 brands ranked in the index capture roughly 95% of all AI citation share. This leaves the remaining 5% to be fought over by the nation's 11,500 independent med spas—representing 96% of all facilities in the country. For these small businesses, AI is not a helpful guide but an insurmountable wall.

"AI did not create the compression we're measuring," Torossian explained. "It exposed it. Two pharmaceutical companies effectively control the answer set. Every med spa in America books patients using one of four companies' molecules. The brand wars play out one tier above the clinic."

This exposure has profound implications for local providers who once relied on word-of-mouth, local advertising, or social media platforms like Instagram to build their client base. As AI becomes the default discovery tool, these smaller practices find themselves algorithmically erased from the initial consideration set. Lacking the resources to build the kind of deep authority signals and sophisticated GEO strategies that AI models reward, they are rendered invisible at the most critical stage of patient acquisition.

Interestingly, the report finds that some board-certified dermatology groups manage to outrank 19 of the 25 top brands, suggesting that in medical categories, a strong, verifiable authority signal can sometimes beat the sheer scale of a national chain. For the thousands of independent med spas, however, the path to AI visibility remains fraught with obstacles.

Outcomes Over Instruments, Platforms Over Providers

The report also reveals a fundamental truth about how consumers approach aesthetic treatments in the age of AI: they search for outcomes, not instruments. Major aesthetic device manufacturers—including InMode, Cutera, BTL Industries, and Hydrafacial—all failed to crack the top 25. This suggests that patient queries are centered on problems ("how to reduce wrinkles") rather than the specific technology used to solve them. Device makers, who often focus their marketing on providers rather than end consumers, have largely failed to create the patient-centric, outcome-focused content that AI crawlers prioritize.

In this new landscape, intermediaries are also gaining immense power. The patient-review marketplace RealSelf scored an 86 in the index, higher than every individual med spa and device brand in the country. By positioning itself as the definitive source for answers to critical patient questions—"is this safe?", "what does it cost?", "how do I find a provider?"—it has become an essential gatekeeper, owning a crucial segment of the AI-driven conversation.

This shift raises critical questions about the nature of trust and the potential for bias. While AI models are designed to surface authoritative information, they are not infallible. Studies have shown that general-purpose AI models can "hallucinate," or generate confident but incorrect information, at rates as high as 15-28% in medical scenarios. The algorithms can also amplify existing biases and omit crucial nuance, presenting a simplified and potentially skewed view of a patient's options. As consumers increasingly place their trust in these systems for health-related advice, the responsibility for the completeness and accuracy of AI-generated answers becomes a pressing ethical concern for the entire healthcare ecosystem.